MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - MaxCyte, Inc. has granted inducement awards to Parmeet Ahuja as part of his appointment as Chief Financial Officer, which includes stock options and restricted stock units (RSUs) [1] Group 1: Inducement Awards - The Compensation Committee granted stock options to purchase 375,000 shares and RSUs for 187,500 shares to Parmeet Ahuja [1] - The stock options have a ten-year term with an exercise price of $0.676, based on the closing price on March 30, 2026 [2] - The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal annual installments [3] Group 2: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [4] - The company utilizes Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [4] - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally [4]